The presence of P. gingivalis and other dental pathogens isn’t enough to incite disease, however. When the oral microbiome is appropriately balanced, no disease is present. The problems occur when the ...

The vaccine targets enzymes produced by the bacterium Porphyromonas gingivalis, to trigger an immune response. This response produces antibodies that neutralise the pathogen's destructive toxins.

First in human phase I clinical study using OMV as an adjuvant for intranasal vaccinationAvacc 10® intranasal booster vaccine induces a mucosal response and no ...

The researchers found that in vitro resistance of subgingival P. gingivalis significantly increased to clindamycin (15-fold increase to 9.3% of patients) and amoxicillin (28-fold increase to 2.8% ...

- Neisserial OMV based Lyme vaccine elicit high antibody titers in mice - Further evidence for Intravacc's versatile multi-disease OMV platform - Data are published in peer reviewed journal ...

Researchers in Italy have demonstrated the efficacy of using modified outer membrane vesicles (OMVs) as a vaccine to protect against coronavirus disease 2019 (COVID-19) in an animal model.

P. gingivalis induces a local inflammatory response that results in oral bone destruction, which is manifested as periodontal disease, an inflammatory disease that affects approximately 100 ...

Keystone Bio announces Porphyromonas Gingivalis Toxic Virulence Factors as a Major Driver of Sporadic Alzheimer’s and Chronic Inflammation.

Novartis’s rMenB-OMV Meningococcal Vaccine and Merck’s V-503 HPV Vaccine Are Expected to Each Garner Blockbuster Sales in Excess of $2 Billion in 2020 ...

Porphyromonas gingivalis-derived OMV vaccine Periodontitis is the most prevalent infectious disease related to oral and systemic health, and a novel prophylaxis to prevent the disease is therefore ...